KEY DETAILS
NPR reported on October 10, 2026 that scant data on serious adverse effects makes it harder to answer scientific and legal questions about how often GLP-1 drugs might cause serious harm like blindness or pancreatitis.
Fortune reported on October 10, 2026 that the GLP-1 story shows how patents can reward discovery and push rivals to develop better drugs.
Gizmodo reported on October 9, 2026, and this was covered in an earlier edition, that Novo Nordisk and Eli Lilly scientists presented data suggesting GLP-1 drugs can slow molecular aging clocks. The studies have not gone through peer review.
Newsmax reported on October 9, 2026, and this was covered in an earlier edition, that research suggests certain foods can stimulate the body's natural production of GLP-1.
MIT Technology Review published a piece on October 9, 2026, covered in an earlier edition, asking whether GLP-1 weight-loss drugs could affect hair, nails, and vision.
NPR reported on October 10, 2026 that there is scant data about serious adverse effects of GLP-1 drugs, which makes it harder to answer scientific and legal questions about how often the drugs might cause serious harm like blindness or pancreatitis. A few other recent pieces touch on patents, aging research, natural GLP-1 production, and side effects that are still being worked out.
NPR's reporting points to a specific problem: scant data about serious adverse effects makes it harder to answer scientific and legal questions. NPR says more than 1,000 reports of optic neuropathy linked to GLP-1s have been submitted to the FDA's adverse events database since 2024, along with 1,928 reports of pancreatitis over the same period. The database relies on mostly voluntary reporting that the agency does not verify, and some doctors do not report suspected adverse events because they cannot confirm the drugs caused the harm rather than preexisting conditions. Lawsuits allege that GLP-1 drug makers failed to warn patients and doctors about serious risks including blindness and pancreatitis. These are allegations, not findings.
A separate piece, published by Fortune on October 10, 2026, uses a desert lizard to explain how patents work in the GLP-1 field. Fortune describes how patents can reward discovery and push rivals to develop better drugs. It notes that a peptide isolated from Gila monster venom in 1990 became the basis for the first GLP-1 medicine approved by the FDA in 2005 to treat type 2 diabetes.
Gizmodo reported on October 9, 2026, in a story covered in an earlier edition, that scientists from Novo Nordisk and Eli Lilly presented data suggesting semaglutide and tirzepatide can slow molecular aging clocks compared to placebo. This is not new. Gizmodo notes that the studies were presented at an anti-aging conference, have not gone through peer review, and were conducted by company scientists rather than independent researchers.
Newsmax published a piece on October 9, 2026, also covered in an earlier edition, saying research suggests certain foods can stimulate the body's natural production of GLP-1, a hormone that helps regulate appetite and blood sugar.
MIT Technology Review published a story on October 9, 2026, covered in an earlier edition, under the headline "We're still figuring out the side effects of GLP-1 weight-loss drugs." It asks whether the drugs could affect hair, nails, and vision. It also notes that the most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, and that the drugs have been linked to pancreatitis and gallstone disease.
Data on serious adverse effects, such as blindness and pancreatitis, is scant, and researchers are still working out other side effects, such as possible effects on hair, nails, and vision. If you take one of these medications or are considering one, your doctor or pharmacist is the right person to ask about your questions.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.